Elosulfase alfa (Vimzim®) is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome, MPS IVA) in patients of all ages.
|30/03/2015||08/05/2015||Full Pharmacoeconomic Evaluation Recommended|
|04/04/2016||08/12/2016||Reimbursement Not Recommended|
The cost effectiveness of elosulfase alfa (Vimizim®) has not been demonstrated. Therefore it is not recommended for reimbursement
The HSE has approved reimbursement following confidential price negotiations: May 2018